OctoPlus publishes Annual Report 2009
(Thomson Reuters ONE) -
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO) announces today the
publication of its Annual Report 2009 and other information related to the
upcoming Annual General Meeting of Shareholders, which will take place on 12 May
2010.
During 2009, OctoPlus has made the transition into a drug delivery company. The
Company is building a portfolio of compounds in development for clients,
utilising its proprietary controlled release technologies. Key events during
2009 were:
§ Locteron successfully progressing through Phase IIb studies: top-line results
to be presented this week at the EASL International Liver Congress
§ Growing adoption of OctoPlus' controlled release technology by the biotech
and pharmaceutical industries through the acquisition of multiple technology
evaluation projects
§ Increasing demand for formulation development and contract manufacturing
services from existing and new customers
§ Successful completion of reorganisation to align organisational structure
with new strategy
These events have resulted in record revenues of ? 19 million, with highest ever
core business (non-Locteron) revenues, and a positive EBITDA for the full year
2009.
The Annual Report is available on the Company's website, www.octoplus.nl. Hard
copies of the report can be requested by sending an e-mail to ir(at)octoplus.nl.
Annual General Meeting of Shareholders: 12 May in Leiden
The Annual General Meeting of Shareholders (AGM) will take place at the
Company's headquarters in Leiden on 12 May 2010 at 14:00 Central European Time
(CET). The agenda and other information regarding the AGM are available in the
Investor Relations section on the Company's website.
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, or
send an e-mail to Investor Relations at IR(at)octoplus.nl.
About OctoPlus
OctoPlus is a drug delivery service company committed to the creation of
improved pharmaceutical products that are based on OctoPlus' proprietary drug
delivery technologies and have fewer side effects, improved patient convenience
and a better efficacy/safety balance than existing therapies. OctoPlus focuses
on the development of long-acting, controlled release versions of known protein
therapeutics, other drugs, and vaccines on behalf of its clients.
The clinically most advanced product incorporating our technology is Biolex
Therapeutics' lead product Locteron(®), a controlled release formulation of
interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed
Locteron exclusively to Biolex in October 2008. Locteron is being manufactured
for Biolex by OctoPlus and is currently in Phase IIb clinical studies.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate active
pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO.
For more information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of OctoPlus and the industry in
which it operates. These statements are based on OctoPlus' current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
[HUG#1401989]
Click here for the press release in PDF: http://hugin.info/137076/R/1401989/356823.pdf
Unternehmensinformation / Kurzprofil:
Datum: 12.04.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 18837
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 269 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OctoPlus publishes Annual Report 2009"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
